Integra LifeSciences (NASDAQ:IART) Announces Earnings Results, Beats Expectations By $0.02 EPS

Integra LifeSciences (NASDAQ:IART) released its quarterly earnings data on Monday. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.02, Briefing.com reports. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the prior year, the firm posted $0.76 earnings per share. Integra LifeSciences’s revenue for the quarter was down .4% on a year-over-year basis.

Integra LifeSciences Stock Up 25.1 %

Shares of Integra LifeSciences stock opened at $24.12 on Tuesday. The company has a market cap of $1.87 billion, a P/E ratio of 83.17, a PEG ratio of 0.66 and a beta of 1.08. The firm has a fifty day moving average of $18.62 and a two-hundred day moving average of $24.46. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. Integra LifeSciences has a one year low of $16.81 and a one year high of $45.42.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Bank of America decreased their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Truist Financial lowered their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Morgan Stanley upped their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th. JMP Securities decreased their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. Finally, Citigroup dropped their price objective on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a research note on Tuesday, October 1st. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $26.50.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.